Poly(ADP-ribose) polymerase (PARP) inhibitors, which are especially effective in cancer associated with BRCA1 or BRCA2 mutation [66], have shown considerable promise in triple-negative breast cancer [67] and may be valuable in treating high-grade serous Type II ovarian cancer [68]. The gene discussed is BRCA1; the disease is ovarian carcinoma.